NPHC's KSA coverage criteria set the de facto GCC access standard for anti-C5 agents, while iptacopan's SFDA registration queue delays oral-agent competition by 12-24 months.
GCC has no unified HTA authority. Access to a PNH therapy requires three sequential steps: SFDA registration in Saudi Arabia (or MOHAP/HAAD registration in the UAE) product by product; a coverage recommendation from NPHC, the Saudi National Programme for Rare and Genetic Diseases, for KSA government hospitals; and separate MOH tender inclusion in each additional GCC state. NPHC does not run a QALY-based HTA process; it evaluates on clinical evidence plus budget impact instead, and its decision functions as the de facto GCC reference: UAE, Qatar, Kuwait, Oman, and Bahrain MOHs typically track the NPHC call within 6-18 months rather than running independent assessments. For PNH specifically, NPHC already covers eculizumab and ravulizumab under defined clinical criteria (FLAER-confirmed clone ≥10% plus symptomatic haemolysis, LDH ≥2× ULN) with access restricted to designated treatment centres.
Iptacopan (Fabhalta), FDA-approved in 2023, is not yet on any GCC formulary. It is working through SFDA's Priority Review pathway for rare-disease products, introduced under the 2020 Rare Disease Regulation, which targets 12-18 months post-FDA/EMA submission versus 18-24 months in the standard lane, a 25-30% timeline reduction; SFDA approves an estimated 15-25 rare-disease products annually under this route. Compassionate use is pending SFDA clearance, and NPHC evaluation has not begun. Once registered, GCC tender pricing for anti-C5-class agents is estimated at 40-55% of US WAC, based on SFDA's reference-pricing precedent: MOHs anchor to the lowest EU comparator price (commonly Portugal, Greece, or Romania) and layer on a further 10-20% negotiation discount. For context, GCC anti-C5 tender pricing today runs SAR 60,000-90,000 per infusion against a US WAC equivalent of SAR 150,000-200,000, or 40-60% of US WAC.
GCC PNH agent access status — 2026
| Drug (Brand / INN) | SFDA / GCC Registration Status | NPHC / MOH Coverage Pathway | GCC Pricing | Key Access Barrier |
|---|---|---|---|---|
| Ultomiris / Soliris (ravulizumab / eculizumab) | SFDA registered; NPHC listed | NPHC covers clone ≥10% + LDH ≥2× ULN, designated centres | Est. 40-60% of US WAC via GCC tender | Other GCC states track NPHC with 6-18m lag |
| Fabhalta (iptacopan) | SFDA registration pending (12-24m post-FDA) | Not yet NPHC formulary; compassionate use pending SFDA | Est. 40-55% of US WAC (SFDA reference pricing precedent) | Registration queue delays oral-agent access |
Sources: SFDA drug registration guidelines 2023; NPHC programme documentation KSA; SFDA Priority Review guidelines 2020; SFDA rare disease regulation 2020; Saudi MOH drug procurement data 2023; GCC tender pricing modelled from SFDA's published reference-pricing methodology, not a named third-party pricing service.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NPHC KSA coverage criteria (FLAER clone threshold, LDH threshold, designated-centre requirement)
- GCC MOH-by-MOH lag analysis for UAE, Qatar, Kuwait, Oman, Bahrain
Delivers
- SFDA Priority Review pathway timeline and requirements for rare-disease oral agents
- GCC tender pricing model (40-55% of US WAC) based on SFDA reference-pricing precedent
Delivers
- GCC tender pricing mechanics — EU reference country selection, negotiation discount range, and infusion-vs-oral price comparison for the PNH class
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why access runs through three sequential gates: SFDA registration, an NPHC coverage recommendation, and separate MOH tender inclusion state by state.
- How NPHC's clinical-evidence-plus-budget-impact model, not a QALY-based HTA process, functions as the de facto GCC reference decision.
- The exact clinical thresholds, a FLAER-confirmed clone of 10% or more and LDH at least 2x ULN, that qualify a PNH patient for eculizumab or ravulizumab.
- Why NPHC restricts access to designated treatment centres rather than opening it to any prescribing hospital in the Kingdom.
- How the 2020 Rare Disease Regulation's Priority Review lane cuts registration to 12-18 months post-FDA/EMA filing, a 25-30% reduction on the standard route.
- Why SFDA's throughput of only 15-25 rare-disease approvals a year still leaves iptacopan's own registration timeline open at 12-24 months.
- Why MOHs anchor tender prices to the lowest EU comparator country, commonly Portugal, Greece, or Romania, then layer on a further 10-20% negotiation discount.
- The SAR 60,000-90,000 per-infusion tender price for anti-C5 agents against a US WAC equivalent of SAR 150,000-200,000.
- Why iptacopan, FDA-approved in 2023, still sits off every GCC formulary while compassionate-use access awaits SFDA clearance.
- The estimated 40-55% of US WAC tender price iptacopan should clear once SFDA registration and NPHC evaluation are complete.
- How UAE, Qatar, Kuwait, Oman, and Bahrain MOHs each track the NPHC KSA coverage call instead of running independent rare-disease HTA.
- Why the 6-18 month lag window means a KSA anti-C5 launch sequence effectively sets the clock for five other GCC markets.
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
This assessment is built from SFDA registration guidance, NPHC programme documentation, and Saudi MOH drug procurement data covering GCC PNH agent access and pricing.
Key sources: SFDA drug registration guidelines (2023) and Priority Review / Rare Disease Regulation guidance (2020); NPHC programme documentation for PNH coverage criteria (2023); Saudi MOH drug procurement data (2023); GCC tender pricing modelled from SFDA's published reference-pricing methodology (EU comparator anchor plus negotiation discount), not from a named third-party analytics source.
- NPHC coverage criteria verified against NPHC programme documentation (2023)
- SFDA registration timeline verified against SFDA Priority Review guidelines (2020) and rare disease regulation (2020)
- GCC tender pricing verified against Saudi MOH drug procurement data (2023)
- GCC MOH lag pattern verified against SFDA drug registration guidelines (2023)
Frequently asked questions
Commission this assessment
AXLRx PNH Payer & HTA (GCC) is built for market access, HEOR, and pricing teams navigating NPHC's coverage criteria, the SFDA rare-disease registration pathway, and GCC tender pricing mechanics across Saudi Arabia, UAE, Qatar, Kuwait, Oman, and Bahrain. Custom assessment in 72 hours.
Specify indication, GCC payer focus (NPHC/SFDA pathway, MOH tender pricing, PA criteria), and commercial question.
AXLRx analyst confirms GCC market scope (KSA-first or pan-GCC), NPHC/SFDA registration analysis, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.